| Clinical Study "Common" Name (formal title) | Number of enrollees | Funding source (pharmaceutical company/National Institutes of Health [NIH]) | Year complete | Primary publication | Full study treatment protocol/patient disposition |
|---|---|---|---|---|---|
|
The Protocol W Randomized Clinical Trial (Effect of Intravitreous Anti Vascular Endothelial Growth Factor vs Sham Treatment: The Protocol for Diabetic Retinopathy: The Protocol W Randomized Clinical Trial) |
328 | National Eye Institute and the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, US Department of Health and Human Services EY14231 (NCT02634333) | 2022 | Maturi RK, et al. JAMA Ophthalmol. 2021;139:701-712. https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2778074 |
|